303 related articles for article (PubMed ID: 35800063)
1. A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies.
Gürgen D; Becker M; Dahlmann M; Flechsig S; Schaeffeler E; Büttner FA; Schmees C; Bohnert R; Bedke J; Schwab M; Wendler JJ; Schostak M; Jandrig B; Walther W; Hoffmann J
Front Oncol; 2022; 12():889789. PubMed ID: 35800063
[TBL] [Abstract][Full Text] [Related]
2. Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma.
Jang J; Rath O; Schueler J; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Kwon GY; Park WY; Lee J; Park SH
Transl Oncol; 2017 Jun; 10(3):304-310. PubMed ID: 28325666
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization.
Sun S; Zhang Z
Front Med; 2016 Mar; 10(1):104-10. PubMed ID: 26926009
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
[TBL] [Abstract][Full Text] [Related]
5. Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures.
Alcaniz J; Winkler L; Dahlmann M; Becker M; Orthmann A; Haybaeck J; Krassnig S; Skofler C; Kratzsch T; Kuhn SA; Jödicke A; Linnebacher M; Fichtner I; Walther W; Hoffmann J
Front Oncol; 2023; 13():1129627. PubMed ID: 37114125
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
7. A new tumorgraft panel to accelerate precision medicine in prostate cancer.
Béraud C; Bidan N; Lassalle M; Lang H; Lindner V; Krucker C; Masliah-Planchon J; Potiron E; Lluel P; Massfelder T; Allory Y; Misseri Y
Front Oncol; 2023; 13():1130048. PubMed ID: 37305585
[TBL] [Abstract][Full Text] [Related]
8. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
9. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
10. Establishment and Characterization of Advanced Penile Cancer Patient-derived Tumor Xenografts: Paving the Way for Personalized Treatments.
Elst L; Van Rompuy AS; Roussel E; Spans L; Vanden Bempt I; Necchi A; Ross J; Jacob JM; Baietti MF; Leucci E; Albersen M
Eur Urol Focus; 2022 Nov; 8(6):1787-1794. PubMed ID: 35537937
[TBL] [Abstract][Full Text] [Related]
11. Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.
Kamli H; Li L; Gobe GC
Ochsner J; 2019; 19(2):138-151. PubMed ID: 31258426
[No Abstract] [Full Text] [Related]
12. Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
Jeong SY; Cho YJ; Ryu JY; Choi JJ; Hwang JR; Kim B; Lee YY; Kim HS; Lee JW
Gynecol Oncol; 2021 Jul; 162(1):173-181. PubMed ID: 33972086
[TBL] [Abstract][Full Text] [Related]
13. Nasopharyngeal carcinoma patient-derived xenograft mouse models reveal potential drugs targeting cell cycle, mTOR, and autophagy pathways.
Li HP; Huang CY; Lui KW; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Kuo YC; Huang MY; Fan HC; Lin AC; Hsieh CH; Chang KP; Lin CY; Wang HM; Chao M; Liu JS; Chang YS; Hsu CL
Transl Oncol; 2023 Dec; 38():101785. PubMed ID: 37713975
[TBL] [Abstract][Full Text] [Related]
14. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade.
Larroquette M; Lefort F; Heraudet L; Bernhard JC; Ravaud A; Domblides C; Gross-Goupil M
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551715
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
[TBL] [Abstract][Full Text] [Related]
17. Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.
Kawaguchi T; Foster BA; Young J; Takabe K
J Mammary Gland Biol Neoplasia; 2017 Jun; 22(2):131-139. PubMed ID: 28451789
[TBL] [Abstract][Full Text] [Related]
18. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
[TBL] [Abstract][Full Text] [Related]
19. An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case report.
Kang Y; Armstrong AJ; Hsu DS
Stem Cell Investig; 2022; 9():8. PubMed ID: 36393918
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
